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background: Single center KATOWICE Registry aimed to assess the impact of chronic kidney disease (CKD) on long-term clinical outcomes in 
patients undergoing PCI and to compare the outcome with first and second generation DES.
Methods: The study group consisted of 1916 consecutive patients treated with either first- (paclitaxel, sirolimus eluting; 34%) or second-
generation (everolimus, zotarolimus, biolimus A9, 66%) DES. There were 314 (16%) patients with CKD. RI was defined as GFR<60ml/min/m2. Major 
adverse cardiac events (MACE) defined as death, stroke or repeat-revascularization were assessed in 1 year follow-up.
results: CKD patients were more often females (50% vs. 33%) and were(71, IQR 64-76 vs. 61 IQR 56-69 years p<0.001) and had higher 
prevalence of co-morbidities: hypertension (92% vs. 85% p<0.01), diabetes (51% vs. 35% p<0.01), lung disease (10% vs. 5% p<0.01), peripheral 
artery disease (18% vs. 10% p<0.01) and anemia (21% vs. 9% p<0.01). At presentation CKD group had lower LVEF (50 IQR 42-58 vs. 55 IQR 48-60 
p<0.01) and more often history of myocardial infarction (55% vs. 49% p<0.01) and PCI (63%% vs. 54% p<0.01). Coronary angiography revealed 
that multivessel coronary artery disease (35% vs. 26% p<0.01), intracoronary thrombus (3% vs. 1.6 p<0.01) and extensive calcifications (7% vs. 
4% p<0.01) were more frequent in patients with CKD. However, the Syntax score was comparable to pts without CKD (16 IQR 8-24 vs. 14 IQR 
8-24). At 1-year follow there were more MACE (death, MI, stroke) [18% vs. 13%, HR=1.45 (95%CI 1.08-1.95), p=0.02] and higher mortality [9% vs. 
2%, HR=3.9 (95%CI 2.4-6.5), p<0.01] in CKD patients. Multivariable Cox analysis revealed, that CKD was an independent risk predictor of death 
[HR=2.3 (95%CI 1.3-3.9) p<0.01] after PCI at 1-year follow-up. Comparison of first and second generation DES in CKD patients showed that use of 
ZES, EES and BES did not attenuate the adverse effect of CKD on MACE (20% vs. 17%).
conclusion: Despite the higher efficacy and safety of second generation DES in all-comer populations, patients with CKD are still at the increased 
risk of death and MACE at 1-year follow-up. Use of second generation DES did not attenuate the higher risk of MACE in CKD patients.
